Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 27, 2024
Daily News
February 27, 2024
- Japan Drug Market Tops 11 Trillion Yen for 1st Time Driven by Oncologics: IQVIA
February 27, 2024
- NCC to Add Cabozantinib, Valemetostat to Pediatric, AYA Cancer Trial
February 27, 2024
- JSMO Panelists Urge Measures to Lure US Biotechs to Fight Drug Loss
February 27, 2024
- Show Change in Development Trends before Seeking 2026 Reform: MHLW to Pharma
February 27, 2024
- Shionogi Seeks Japan Nod for Akili’s Therapeutic App for Kids with ADHD
February 27, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…